References
- 1. Buzzetti R, Tuomi T, Mauricio D, Pietropaolo M, Zhou Z, Pozzilli P et al. Management of Latent Autoimmune Diabetes in Adults: A Consensus Statement from an International Expert Panel. Diabetes. 2020;69(10):2037-2047.10.2337/dbi20-0017780971732847960
- 2. Hernández M, Mauricio D. Latent Autoimmune Diabetes in Adults: A Review of Clinically Relevant Issues. Advances in Experimental Medicine and Biology; 2020. p. 29-41.10.1007/5584_2020_53332424495
- 3. Pieralice S, Pozzilli P. Latent Autoimmune Diabetes in Adults: A Review on Clinical Implications and Management. Diabetes Metab J. 2018;42(6):451-464.10.4093/dmj.2018.0190630044030565440
- 4. Classification of diabetes mellitus. Geneva: World Health Organization; 2019.
- 5. Nishimura A, Matsumura K, Kikuno S, et al. Slowly Progressive Type 1 Diabetes Mellitus: Current Knowledge And Future Perspectives. Diabetes Metab Syndr Obes. 2019;12:2461-2477.10.2147/DMSO.S191007688659231819572
- 6. Naik R, Brooks-Worrell B, Palmer J. Latent Autoimmune Diabetes in Adults. The Journal of Clinical Endocrinology & Metabolism. 2009;94(12):4635-4644.10.1210/jc.2009-112019837918
- 7. Zinman B, Kahn S, Haffner S, O’Neill M, Heise M, Freed M. Phenotypic Characteristics of GAD Antibody-Positive Recently Diagnosed Patients With Type 2 Diabetes in North America and Europe. Diabetes. 2004;53(12):3193-3200.10.2337/diabetes.53.12.319315561950
- 8. Andersen M. New Insights into the Genetics of Latent Autoimmune Diabetes in Adults. Current Diabetes Reports. 2020;20(9).10.1007/s11892-020-01330-y32725517
- 9. Jörns A, Wedekind D, Jähne J, Lenzen S. Pancreas pathology of latent autoimmune diabetes in adults (LADA) in patients and in a LADA rat model compared with type 1 diabetes. Diabetes. 2020;69:624–633.10.2337/db19-086531974139
- 10. Buzzetti R, Zampetti S, Maddaloni E. Adult-onset autoimmune diabetes: current knowledge and implications for management. Nature Reviews Endocrinology. 2017;13(11):674-686.10.1038/nrendo.2017.9928885622
- 11. Chen W, Chen X, Zhang M, Huang Z. The association of human leukocyte antigen class II (HLA II) haplotypes with the risk of Latent autoimmune diabetes of adults (LADA): Evidence based on available data. Gene. 2021;767:145177.10.1016/j.gene.2020.14517732998048
- 12. Laugesen E, Østergaard JA, Leslie RD; Danish Diabetes Academy Workshop and Workshop Speakers. Latent autoimmune diabetes of the adult: current knowledge and uncertainty. Diabet Med. 2015 Jul;32(7):843-852.10.1111/dme.12700467629525601320
- 13. Desai M, Zeggini E, Horton V, Owen K, Hattersley A, Levy J et al. An association analysis of the HLA gene region in latent autoimmune diabetes in adults. Diabetologia. 2006;50(1):68-73.10.1007/s00125-006-0513-z307620717143607
- 14. Maddaloni E, Moretti C, Mignogna C, Buzzetti R. Adult-onset autoimmune diabetes in 2020: An update. Maturitas. 2020 Jul;137:37-44.10.1016/j.maturitas.2020.04.01432498935
- 15. Hawa M, Kolb H, Schloot N, Beyan H, Paschou S, Buzzetti R et al. Adult-Onset Autoimmune Diabetes in Europe Is Prevalent With a Broad Clinical Phenotype: Action LADA 7. Diabetes Care. 2012;36(4):908-913.10.2337/dc12-0931360950423248199
- 16. Lampasona V, Pittman DL, Williams AJ, et al. Islet Autoantibody Standardization Program 2018 Workshop: Interlaboratory Comparison of Glutamic Acid Decarboxylase Autoantibody Assay Performance. Clin Chem. 2019;65(9):1141-1152.10.1373/clinchem.2019.304196893613531409598
- 17. Zhu Y, Qian L, Liu Q, et al. Glutamic Acid Decarboxylase Autoantibody Detection by Electrochemiluminescence Assay Identifies Latent Autoimmune Diabetes in Adults with Poor Islet Function. Diabetes Metab J. 2020;44(2):260-266.10.4093/dmj.2019.0007718896831769235
- 18. Tiberti C, Giordano C, Locatelli M, Bosi E, Bottazzo G, Buzzetti R et al. Identification of Tyrosine Phosphatase 2(256-760) Construct as a New, Sensitive Marker for the Detection of Islet Autoimmunity in Type 2 Diabetic Patients: The Non-Insulin Requiring Autoimmune Diabetes (NIRAD) Study 2. Diabetes. 2008;57(5):1276-1283.10.2337/db07-087418332100
- 19. Li XH, Yu FF, Zhou YH, He J. Association between alcohol consumption and the risk of incident type 2 diabetes: A systematic review and dose-response meta-analysis. Am J Clin Nutr. 2016;103(3):818-829.10.3945/ajcn.115.11438926843157
- 20. Carlsson S. Environmental (Lifestyle) Risk Factors for LADA. Current Diabetes Reviews. 2019;15(3):178-187.10.2174/157339981466618071615025330009710
- 21. Hjort R, Ahlqvist E, Carlsson PO, et al. Overweight, obesity and the risk of LADA: results from a Swedish case-control study and the Norwegian HUNT Study. Diabetologia. 2018;61(6):1333-1343.10.1007/s00125-018-4596-0644899829589073
- 22. Löfvenborg JE, Ahlqvist E, Alfredsson L, Andersson T, Groop L, Tuomi T, Wolk A, Carlsson S. Consumption of red meat, genetic susceptibility, and risk of LADA and type 2 diabetes. Eur J Nutr. 2021 Mar;60(2):769-779.10.1007/s00394-020-02285-2790003632444887
- 23. Hjort R, Alfredsson L, Andersson T, et al. Family history of type 1 and type 2 diabetes and risk of latent autoimmune diabetes in adults (LADA). Diabetes Metab. 2017;43(6):536-542.10.1016/j.diabet.2017.05.01028669512
- 24. Banerjee P, Khan NZ, Singh ST, Singh N, Qamar I. Latent autoimmune diabetes in adults: complication, management and treatment modalities. Endocrinol Metab Int J.2019;7(3):67-72.10.15406/emij.2019.07.00246
- 25. Zaharia OP, Bobrov P, Strassburger K, et al. Metabolic Characteristics of Recently Diagnosed Adult-Onset Autoimmune Diabetes Mellitus. J Clin Endocrinol Metab. 2018;103(2):429-437.10.1210/jc.2017-0170629220505
- 26. Rajkumar V, Levine SN. Latent Autoimmune Diabetes. In: StatPearls. Treasure Island (FL): StatPearls Publishing; July 18; 2021.
- 27. Fadiga L, Saraiva J, Catarino D, Frade J, Melo M, Paiva I. Adult-onset autoimmune diabetes: comparative analysis of classical and latent presentation. Diabetol Metab Syndr. 2020;12(1):107.10.1186/s13098-020-00616-1771331533292447
- 28. Mishra R, Hodge KM, Cousminer DL, Leslie RD, Grant SFA. A Global Perspective of Latent Autoimmune Diabetes in Adults. Trends Endocrinol Metab. 2018;29(9):638-650.10.1016/j.tem.2018.07.00130041834
- 29. Castelblanco E, Hernández M, Castelblanco A, et al. Low-grade Inflammatory Marker Profile May Help to Differentiate Patients With LADA, Classic Adult-Onset Type 1 Diabetes, and Type 2 Diabetes. Diabetes Care. 2018;41(4):862-868.10.2337/dc17-166229358494
- 30. Koufakis T, Katsiki N, Zebekakis P, Dimitriadis G, Kotsa K. Therapeutic approaches for latent autoimmune diabetes in adults: One size does not fit all. J Diabetes. 2020;12(2):110-118.10.1111/1753-0407.1298231449359
- 31. Gribble FM, Ashcroft FM. Differential sensitivity of beta-cell and extrapancreatic KATP channels to gliclazide. Diabetologia. 1999;42:845-848.10.1007/s00125005123610440127
- 32. Engler RL, Yellon DM. Sulfonylurea KATP Blockade in Type II Diabetes and Preconditioning in Cardiovascular Disease. Circulation. 1996;94:2297-2301.10.1161/01.CIR.94.9.2297
- 33. Heller SR; ADVANCE Collaborative Group. A summary of the ADVANCE Trial. Diabetes Care. 2009;32 Suppl 2(Suppl 2):S357-S361.10.2337/dc09-S339281145119875581
- 34. Avogaro A. Treating diabetes today with gliclazide MR: a matter of numbers. Diabetes Obes Metab. 2012 Jan;14 Suppl 1:14-19.10.1111/j.1463-1326.2011.01508.x22118706
- 35. Zhang Z, Yan X, Wu C, et al. Adding vitamin D3 to the dipeptidyl peptidase-4 inhibitor saxagliptin has the potential to protect β-cell function in LADA patients: A 1-year pilot study. Diabetes Metab Res Rev. 2020;36(5):e3298.10.1002/dmrr.329832043288
- 36. Pinheiro MM, Pinheiro FMM, Diniz SN, Fabbri A, Infante M. Combination of vitamin D and dipeptidyl peptidase-4 inhibitors (VIDPP-4i) as an immunomodulation therapy for autoimmune diabetes. Int Immunopharmacol. 2021;95:107518.10.1016/j.intimp.2021.10751833756226
- 37. Latif A, Gastelum AA, Sood A, Reddy JT. Euglycaemic diabetic ketoacidosis in a 43-year-old woman with type 2 diabetes mellitus on SGLT-2 inhibitor (empagliflozin). BMJ Case Rep. 2020;13(6):e235117.10.1136/bcr-2020-235117728229332513767
- 38. White-Cotsmire AJ, Healy AM. Ketogenic Diet as a Trigger for Diabetic Ketoacidosis in a Misdiagnosis of Diabetes: A Case Report. Clin Diabetes. 2020;38(3):318-321.10.2337/cd20-0001736445832699486
- 39. Pozzilli P, Leslie RD, Peters AL, et al. Dulaglutide treatment results in effective glycaemic control in latent autoimmune diabetes in adults (LADA): A post-hoc analysis of the AWARD-2, -4 and -5 Trials. Diabetes Obes Metab. 2018;20(6):1490-1498.10.1111/dom.1323729377522
- 40. Liu B, Xiang Y, Liu Z, Zhou Z. Past, present and future of latent autoimmune diabetes in adults. Diabetes Metab Res Rev. 2020;36(1):e3205.10.1002/dmrr.320531318117
- 41. Wod M, Thomsen RW, Pedersen L, Yderstraede KB, Beck-Nielsen H, Højlund K. Lower mortality and cardiovascular event rates in patients with Latent Autoimmune Diabetes In Adults (LADA) as compared with type 2 diabetes and insulin deficient diabetes: A cohort study of 4368 patients. Diabetes Res Clin Pract. 2018;139:107-113.10.1016/j.diabres.2018.02.04229518492
- 42. Issar T, Yan A, Kwai NCG, et al. Altered peripheral nerve structure and function in latent autoimmune diabetes in adults. Diabetes Metab Res Rev. 2020;36(3):e3260.10.1002/dmrr.326031833206
- 43. Alam U, Jeziorska M, Petropoulos IN, et al. Latent autoimmune diabetes of adulthood (LADA) is associated with small fibre neuropathy. Diabet Med. 2019;36(9):1118-1124.10.1111/dme.1388830575096
- 44. Carlsson S. Etiology and Pathogenesis of Latent Autoimmune Diabetes in Adults (LADA) Compared to Type 2 Diabetes. Front Physiol. 2019;10:320.10.3389/fphys.2019.00320644405930971952
- 45. Frazier AR. Correct Diabetes Diagnosis and Treatment Allows Sailor to Remain on Active Duty. Mil Med. 2020;185(9-10):e1843-e1846.10.1093/milmed/usaa01232373933
- 46. O’Neal KS, Johnson JL, Panak RL. Recognizing and Appropriately Treating Latent Autoimmune Diabetes in Adults. Diabetes Spectr. 2016; 29(4):249-252.10.2337/ds15-0047511152827899877